Perrigo Company plc (NYSE:PRGO) Q1 2024 Earnings Call Transcript May 7, 2024 8:30 AM ET
Company Participants
Brad Joseph - VP, Global IR
Patrick Lockwood-Taylor - President and CEO
Eduardo Bezerra - CFO
Conference Call Participants
Susan Anderson - Canaccord Genuity
Chris Schott - JPMorgan
Daniel Biolsi - Hedgeye
Operator
Good morning, ladies and gentlemen, and welcome to Perrigo First Quarter 2024 Financial Results Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] This call is being recorded on Tuesday, May 7, 2024. I would now like to turn the conference over to Brad Joseph, VP, Global Investor relations. Please go ahead.
Brad Joseph
Good morning and good afternoon, everyone. Welcome to Perrigo's first quarter 2024 earnings conference call. I hope you all had a chance to review our press release issued this morning. A copy of the releases and presentation for today's discussion are available within the Investors section of the perrigo.com website. Joining today's call are President and CEO, Patrick Lockwood-Taylor, and CFO, Eduardo Bezerra.
I would like to remind everyone that during this call, participants will make certain forward-looking statements. Please refer to the important information for shareholders and investors and safe harbor language regarding these statements in our releases issued earlier today.
A few items before we start. First, unless stated, all financial results discussed and presented are on a continuing operations basis. Continuing operations for the quarter include the HRA Rare Diseases business, which was classified as held for sale after the quarter end and does not include any contributions from the divested RX business, which was accounted for as discontinued operations prior to its sale. Second, organic growth excludes acquisitions, divestitures, exited product lines and currency in both comparable periods. All comments related to constant currency removed the impact of currency translation versus the prior year by applying the exchange rates used in the comparable measurement in the prior year's financial statements. And third, Patrick's discussion will focus solely on non-GAAP results except as otherwise noted. See the appendix for additional details and reconciliations of all non-GAAP financial measures presented.
And with that, I'm pleased to turn the call to Patrick.
Patrick Lockwood-Taylor
Thank you, Brad. Good morning, good afternoon, everyone. I'd like to begin our call today by emphasizing the important strides we have made to further our One Perrigo strategy, deliver on our purpose to make lives better through trusted health and wellness solutions accessible to all.